Evotec (NASDAQ:EVO) Sets New 1-Year Low – Time to Sell?

Evotec AG (NASDAQ:EVO)’s share price reached a new 52-week low on Monday . The company traded as low as $1.89 and last traded at $1.89, with a volume of 12713 shares trading hands. The stock had previously closed at $1.93.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on EVO shares. HC Wainwright decreased their price target on Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, July 15th. Wall Street Zen cut Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a report on Wednesday, July 15th. Finally, Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evotec currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Evotec Trading Down 2.1%

The business has a 50 day moving average of $2.30 and a 200 day moving average of $2.74. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Optiver Holding B.V. boosted its position in Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after purchasing an additional 242,973 shares during the period. WCM Investment Management LLC lifted its stake in Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after buying an additional 67,917 shares in the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Evotec in the first quarter worth about $28,000. SmartHarvest Portfolios LLC acquired a new position in shares of Evotec in the first quarter worth about $44,000. Finally, XTX Topco Ltd increased its position in shares of Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after acquiring an additional 3,709 shares in the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.